All In Biotech

Drug Trial Radar · NCT07847411

Study of Velaglucerase Beta ERT in Children With Gaucher Disease

A Multi-center, Open-label Study to Evaluate the Safety and Efficacy of Velaglucerase Beta Enzyme Replacement Therapy in Children With Gaucher Disease

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 16, 2026

Primary completion

Feb 25, 2028

Study completion Feb 25, 2028

Sponsor

Lead sponsor
CANbridge Life Sciences Ltd.Industry
Sponsor type
Industry
First posted
Sep 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, multicenter, open-label, single-arm study to evaluate the safety, efficacy, PK, PD, and immunogenicity of velaglucerase beta in untreated children with GD1 or GD3 for 39 weeks.

Conditions

  • Gaucher Disease
  • Gaucher Disease Type 1
  • Gaucher Disease Type 3

Interventions

  • Velaglucerase betaDrug

    All subjects will receive velaglucerase beta 60 U/kg IV Q2W for 37 weeks with two weeks of follow-up through Week 39 (9 months).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EndpointsTime frame: From Baseline to Week 39
  2. Mean percent change in MN spleen volumeTime frame: From Baseline to Week 39

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Room 202, 2nd Floor, 780 Cailun Road, Pilot Free Trade Zone

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.